# Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

> **NCT00774800** · PHASE2 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Humalog
- **DRUG:** Humulin-R
- **DRUG:** Recombinant human hyaluronidase PH20 (rHuPH20)
- **OTHER:** Liquid meal

## Key facts

- **NCT ID:** NCT00774800
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774800, "Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00774800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*